近日,北京梅尔森医药宣布,其研发的全球首款针对增殖期浅表性婴儿血管瘤的局部外用治疗制剂——马来酸噻吗洛尔凝胶,已于2025年9月30日正式获得国家药品监督管理局(NMPA)批准上市。记者获悉,医渡科技项目咨询与评估团队提供的关键的市场调研和项目调研分析服务,为药物的研发与上市路径提供支持。婴幼儿血管瘤是常见儿科皮肤病,多数为浅表性。约半数病例在血管瘤消退后留有后遗症,增殖期可能引发严重并发症,影响...
Source Link近日,北京梅尔森医药宣布,其研发的全球首款针对增殖期浅表性婴儿血管瘤的局部外用治疗制剂——马来酸噻吗洛尔凝胶,已于2025年9月30日正式获得国家药品监督管理局(NMPA)批准上市。记者获悉,医渡科技项目咨询与评估团队提供的关键的市场调研和项目调研分析服务,为药物的研发与上市路径提供支持。婴幼儿血管瘤是常见儿科皮肤病,多数为浅表性。约半数病例在血管瘤消退后留有后遗症,增殖期可能引发严重并发症,影响...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.